Semarion raises £2.14 million GBP seed funding

Semarion’s cell assaying platform turns adherent cells into liquid reagents to enable novel drug screening methodologies

24-Feb-2022 - Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced that it has closed a £2.14 million GBP seed funding round. The investment round was led by Parkwalk Advisors, ...

ibidi Awarded with the Export Award Bavaria: Special Edition 2021

02-Dec-2021 - For its excellent crisis strategy during the pandemic, ibidi GmbH has been awarded the Export Award Bavaria 2021: Special Edition 2021, in the category, "Successful Order Processing in Corona Times." The award, which has been presented since 2007 to small- and medium-sized companies that work ...

Axiogenesis and Metrion Biosciences announce stem cell collaboration

Collaboration to develop human iPSC-derived cardiomyocytes and neurons for translational drug discovery

08-Nov-2016 - Axiogenesis AG, a preclinical biotechnology company specialising in the development and production of induced pluripotent stem cell (iPSC)-derived cells and tissues for preclinical applications, and Metrion Biosciences Ltd, the specialist ion channel CRO, have signed a collaboration agreement to ...

Sigma Life Science Announces Scientific Advisory Board to drive ADME/Tox program

Board to Provide Counsel on New Solutions for Pre-clinical Testing with Sigma’s CompoZr® Zinc Finger Nuclease (ZFN) Technology

14-Jun-2011 - Sigma Life Science, the biological products and services research business of Sigma-Aldrich Corporation, announced the formation of an ADME/Toxicology Scientific Advisory Board (ADME/Tox SAB) in an effort to help drive development of new cell-based assays using the Company's innovative CompoZr ...

Chris Beaver joins Pharmanet as Director, Immunochemistry Services

02-Dec-2010 - PharmaNet Development Group, Inc. announced that Chris Beaver, PhD has joined the Company as Director, Immunochemistry Services. Dr. Beaver is responsible for leading the immunochemistry team within the Company’s bioanalytical laboratories and expanding its large molecule services, including ...

Microfluidic device allows collection, analysis of hard-to-handle immune cells

Ability to gently collect neutrophils may improve understanding of immune response to serious injury

01-Sep-2010 - A team led by Massachusetts General Hospital (MGH) scientists has developed a new microfluidic tool for quickly and accurately isolating neutrophils – the most abundant type of white blood cell – from small blood samples, an accomplishment that could provide information essential to better ...

Max Planck Innovation awards license for actin marker LifeAct

Max Planck Innovation and ibidi sign license agreement for cytoskeleton research

28-Jul-2010 - Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made ...

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

03-Nov-2009 - InteRNA Technologies B.V. and the Dana-Farber Cancer Institute have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Under the research collaboration with Associate Professor William C. Hahn, MD, PhD (Department of Medical Oncology), InteRNA’s ...

InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer

24-Apr-2009 - InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer. Under the research collaboration with professor Jack Schalken (Laboratory of Experimental Urology), InteRNA’s unique ...

ibidi establishes partnership with Seahorse Bioscience

05-Feb-2009 - ibidi GmbH announced a partnership with Seahorse Bioscience, Inc. of Billerica; Main, USA. Under the terms of the agreement ibidi will exclusively distribute the products of Seahorse Bioscience in Germany and Austria. With this partnership ibidi further strengthens its position as a service ...